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abstract
The International Cancer Research Partnership (ICRP) is an active network of cancer research funding or-
ganizations, sharing information about funded research projects in a common database. Data are publicly
available to enable the cancer research community to find potential collaborators and avoid duplication. This
study presents an aggregated analysis of projects funded by 120 partner organizations and institutes in 2006-
2018, to highlight trends in cancer research funding. Overall, the partners’ funding for cancer research in-
creased from $5.562 billion (bn) US dollars (USD) in 2006 to $8.511bn USD in 2018, an above-inflation
increase in funding. Analysis by the main research focus of projects using Common Scientific Outline categories
showed that Treatment was the largest investment category in 2018, followed by Early Detection, Diagnosis, and
Prognosis; Cancer Biology; Etiology; Control, Survivorship, and Outcomes; and Prevention. Over the 13 years
covered by this analysis, research funding into Treatment and Early Detection, Diagnosis, and Prognosis had
increased in terms of absolute investment and as a proportion of the portfolio. Research funding in Cancer
Biology and Etiology declined as a percentage of the portfolio, and funding for Prevention and Control, Sur-
vivorship and Outcomes remained static. In terms of cancer site–specific research, funding for breast cancer
and colorectal cancer had increased in absolute terms but declined as a percentage of the portfolio. By contrast,
investment for brain cancer, lung cancer, leukemia, melanoma, and pancreatic cancer increased both in
absolute terms and as a percentage of the portfolio.
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BACKGROUND
Collaboration between research funding organizations
is becoming increasingly important at an international
level, to allow coordination of investment in common
identified priority areas, reduce duplication, and fast-
track outcomes. The International Cancer Research
Partnership1 (ICRP) is an alliance that in 2021 in-
cludes more than 140 cancer research organizations
from the United States, Canada, Europe, Japan, and
Australia. ICRP maintains the only public source,
worldwide, of current and past grants, totaling more
than $80bn US dollars (USD) in cancer research
funding since 2000. ICRP member organizations
submit project-level data for their research portfolios to
the ICRP database2 including PI name, host institu-
tion, city, country, funding organization, project title,
abstract, start date, end date, and total funding
amount for that period. Each project in the database is
assigned to one or more cancer sites and research
types. The research type classification (Common
Scientific Outline or CSO) includes 34 codes, grouped
into six categories (Biology, Etiology, Prevention, Early
Diagnosis and Prognosis, Treatment, and Survivorship
and Cancer Control).3 All fields (with the exception of
project funding amount) are visible on the ICRP public
website, and project funding amount is visible to
partners who contribute data. The database includes
current and historic projects, enabling researchers to
identify potential collaborators and to avoid duplicating
previous or existing research. The primary objective of
this analysis was to assess if investment in types of
research (CSO) and cancer sites had changed sig-
nificantly between 2006 and 2018. As it was not
possible to present detailed trends for all cancer sites
within this paper, secondary objectives were to assess
trends in investment in CSO categories for a cancer site
with the highest percent increase in funding during
this timeframe (pancreatic cancer) and to look at
detailed trends in research types with the lowest in-
vestment levels, namely, prevention (CSO 3) and
survivorship (CSO 6). This analysis and the accom-
panying data pack were produced to enable the
partners, and the wider cancer research funding
community, to monitor changing patterns in research
investment internationally and to inform future stra-
tegic planning.
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METHODOLOGY
The ICRP database includes projects across the spectrum of
cancer research. Projects within the database are for
hypothesis-driven research or resources and infrastructure to
support these. Some cancer research investments by funding
partners (eg, capital expenditure on buildings for cancer
research) are not included. Calendar Years (CY)2006-
CY2018 were selected for this analysis, as project-level
data were complete for all of the largest ICRP member
funding organizations or consortia during this timeframe. In
particular, to avoid sampling bias, CY2006 was selected as
the start year because changes to project and/or award
reporting at USNational Institutes of Health (NIH) in FY07 are
reflected in the ICRP database only from CY2006 onward.
Figures for NIH investment in CY2005 and earlier in the ICRP
database were not comparable with those for CY2006 and
later and could have given rise to artificially low figures for
CY2005, thus over-representing the increase for 2018. For
the organizations included in this analysis, in 2018, the
majority of $8,396 million (M) USD investment came from
organizations that had also been in existence in 2006–data
for these organizations were included in full for the period
2006-2018. Nearly $115M USD of the 2018 investment
came from organizations whose cancer research programs
had started after 2006, thereby representing real new in-
vestment in cancer research during this timeframe. Details of
projects active in CY2006-CY2018 (inclusive) were extracted
from the database and project dollars per CY calculated
based on budget start and end dates, and days in a specific
calendar year. Cancer site and CSO investments were cal-
culated using percent allocations per project to avoid double
accounting. All project funding amounts that were not in USD
were converted to USD using the average CY2018 exchange
rate, to avoid confounding underlying trends with those based
on year-on-year currency fluctuations. Trends in CSO or
cancer site investment were calculated using proportional
annual investment, and significance was assessed using
regression lines and R2 values. Statistical analysis suggested
that polynomial regressions provided the best fit for the data
because most trends were not linear.
Normalization of investment figures means that the figures
presented here differ from those in individual partner or-
ganizations’ annual reports, which may represent fiscal
years or other accounting conventions. A top-level as-
sessment of the effect of inflation over 2006-2018 was
calculated using the CPI Inflation calculator.4
All projects in the portfolio were coded to one or more cancer
sites and CSO categories. Cancer sites used by ICRP3 consist
of 61 site codes, linked to one ormore neoplasm codes in the
International Classification of Diseases-10.5 Percent invest-
ment in site-specific cancers was compared with global
cancer incidence and mortality rates for the same sites for
2018, sourced from the Global Cancer Observatory.6
In 2014, the ICRP partners migrated to a new version of the
CSO (v2) and all earlier projects in the database were re-
coded. As part of this migration, a statistical assessment of
inter-rater reliability was conducted for both the CSO and
cancer sites. Agreement was in the very good range for
major CSO categories (Cohen’s kappa coefficient 0.85) and
cancer sites (Cohen’s kappa: 0.80) and in the good range
for minor categories of the CSO (Cohen’s kappa: 0.69).7-9
In addition, projects that were wholly or partially relevant to
childhood, adolescent, and young adult (CYA) cancers
were tagged. Project dollars from organizations that ex-
clusively funded CYA cancers were included in full. In-
vestment in CYA projects from organizations funding
research in both childhood and adult cancers was calcu-
lated using a combination of the CYA cancer project tag and
a filter to exclude any cancer site investment that was not
common in childhood, to avoid overstating investment in
CYA cancers.
RESULTS
Trends in the Overall Portfolio
Over the 10-year period CY2006-CY2018, research in-
vestment by ICRP partner organizations increased from
$5.5bn USD to $8.5bn USD and funded project numbers
increased from 34,305 in 2006 to 44,131 in 2018. This
increase in investment to 2018 was a real increase in
CONTEXT
Key Objective
This study provides, for the first time, an in-depth view of the evolving landscape of global cancer research funding from 2006
to 2018, based on project-level data provided by cancer research funding organizations classified by cancer type and
research type.
Knowledge Generated
The results show that funding for cancer research shifted to be more translational and clinical in focus. Funding for all major
cancer types increased between 2006 and 2018, and this study highlights that additional funding was allocated to cancers
of high incidence or mortality.
Relevance
This study highlights gap areas for future research to enable strategic, focused research and funding decisions.
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funding of 24% above inflation. Most of the increase resulted
from additional investments of more than $2.9bn USD by
partner organizations that were in existence in 2006, with a
substantial additional contribution (nearly $115M USD) from
new organizations founded since 2006 and whose invest-
ment in cancer research programs started after 2006. In-
ternationally, the government sector was the biggest funder of
cancer research (90%) in 2006 and its contribution to overall
funding was similar in 2018 (93%). During CY2009-CY2012,
there was a peak in funding (not shown), largely attributable
to additional investments of the US Government’s American
Recovery and Reinvestment Act (ARRA), which added
around $0.5-$1bn USD per annum to research investment
during this period, primarily to projects in the United States.
The analysis included data from 120 funding organizations
with active research projects during the time period se-
lected for the analysis. The largest contributor ($7.3bn USD
in 2018) to the overall portfolio was the US NIH, including
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FIG 1. (A) Investment by type of research between 2006 and 2018 (including absolute investment by USD—clustered columns, y axis and as a
percentage of the annual portfolio USD value, secondary y axis, and scatter plots with regression lines). (B) Equivalent investment figures by non-
NIH partner organizations. CSO, Common Scientific Outline; M, million; NIH, US National Institutes of Health; USD, US dollars.
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all investment from the National Cancer Institute and rel-
evant research from other NIH Institutes, as defined by the
NIH’s internal cancer spend category. Other organizations
contributed research totaling $1.2bn USD in 2018 to the
analysis.
Trends by Type of Research (CSO) and Cancer Site
Analysis by the main focus of research using CSO
categories3 showed that treatment (CSO 5, 29%) was the
largest investment category in 2018, followed by Cancer
Biology (CSO 1, 26%); Early Detection, Diagnosis, and
Prognosis (CSO 4, 15%); Etiology (CSO 2, 12%); Control,
Survivorship, and Outcomes (CSO 6, 9%); and Prevention
(CSO 3, 9%) (Fig 1A). As the US NIH was the largest
contributor to the data set, trends for all other organizations
were analyzed separately (Fig 1B), showing similar patterns
to NIH data: Treatment (CSO 5, 33%) was the largest
category, followed by Cancer Biology (CSO 1, 29%); Early
Detection, Diagnosis, and Prognosis (CSO 4, 17%); Etiology
(CSO 2, 8%); Control, Survivorship, and Outcomes (CSO 6,
8%); and Prevention (CSO 3, 5%).
Each project included in the analysis was coded to one or
more cancer site(s).3 A breakdown of the portfolio by site
revealed changes in research funding emphasis from 2006
to 2018. Not site-specific research (ie, research that was
not linked to any one specific cancer site or that was equally
relevant to all cancers, eg, pain control) accounted for an
increased percentage of the portfolio (from 32.3% of overall
investment in 2006 to 33.8% in 2018). Analysis of the
cancer-site specific research investment (66.2% of the
portfolio in 2018) revealed changing patterns in invest-
ment. Absolute levels of investment had increased over the
period 2006-2018 for all 10 of the cancer sites receiving the
highest level of investment in 2018. The results for these
cancer sites showed a significant decline in the proportion
of funding to breast cancer from 2006 (but an increase in
absolute investment from $787M USD in 2006 to $993M
USD in 2018) (Fig 2). Funding for colorectal cancer showed
only a small increase in absolute terms ($381M USD in
2006 to $385M USD in 2018) and a decline in terms of
proportional investment (10.3%-6.8%), dropping from the
third highest to sixth highest investment. Similarly, funding
for prostate cancer showed a small increase in absolute
terms ($397M USD in 2006 to $450M USD in 2018), but a
decline in terms of proportional investment (10.7%-8%).
By contrast, investment for lung cancer, leukemia, brain
cancers, non-Hodgkin lymphoma, pancreatic cancer,
melanoma, and ovarian cancer increased both in absolute
terms and as a percentage of the portfolio.
Over the period 2006-2018, CYA cancer research
accounted for 5% of the annual funding portfolio on av-
erage (range, 4.6%-5.8%) and absolute investment had
increased from $278M to $584M USD for projects wholly
and partially related to CYA cancers. Analysis of the types of
cancer researched in CYA cancer projects (Fig 3) dem-
onstrated that leukemia, brain, and sarcoma (soft tissue)
were the major research focus areas for projects in the
portfolio in 2018.
Focus on Detailed Trends in Pancreatic Cancer,
Prevention Research (CSO 3), and Survivorship Research
(CSO 6)
In this paper, it was not possible to present detailed trends
for all cancer types and research types. Detailed data have
been made available for analysis using the public data set
accompanying this paper, and therefore, in this paper, we
chose to focus on the cancer type showing the highest
increase in percent investment in this time period (pan-
creatic cancer) and highlight trends in prevention and
cancer survivorship research (the research areas receiving
the lowest level of investment overall). Absolute investment
in pancreatic cancer research increased threefold between
2006 ($62M USD) and 2018 ($259m USD), as did pro-
portional investment (1.7%-4.6%), with a significantly
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FIG 2. Cancer site: change in %
investmenta between 2006 and 2018
versus incidence and mortality %
(2018)—major sites by investment. aFor
clarity, individual years’ data points are
omitted from the regression line for
trends in investment in specific cancer
sites (2006-2018) USD, US dollars.
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increased focus on research into diagnosis (CSO 4) and a
corresponding reduction in proportional investment in
etiology (CSO2) (Fig 4). The increased investment in
treatment (CSO 5) was primarily driven by a notable in-
crease in absolute or proportional investment in preclinical
discovery and development of systemic therapies (CSO 5.3)
(Fig 4, inset).
The overall proportion of research investment in prevention
(CSO 3) had not changed markedly between 2006 and
2018 (average of 7.5%, range, 7.1%-8.8%). The small
upward trend in absolute investment was not statistically
significant (R2 , 0.5, not shown), and the trend in annual
percent investment was not conclusive (regression plot, Fig
1A). Increased investment in resources and infrastructure
to support prevention was observed (CSO 3.6) in this
timeframe, as was research investment in nondietary be-
havioral interventions (CSO 3.1) (Fig 5).
As the number of cancer survivors globally is increasing,
trends in investment levels were assessed. Absolute levels
of investment in survivorship research (CSO 6.1) had
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pattern of investment in 2018 for cancer
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to childhood cancer. CSO, Common Sci-
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increased from $116M USD in 2006 to $242M USD in
2018, and proportional investment rose significantly from
2.1% of the portfolio in 2006 to 2.8% in 2018 (R2 = 0.87).
Most research in this area was not specific to any one
cancer site (Fig 6).
DISCUSSION
In conclusion, ICRP partners’ project-level funding data
coded to CSO and cancer site provide a unique resource for
analyzing current and historic activity in international
cancer research investment. Whether data were viewed by
absolute investment levels or by percentage of annual in-
vestment, the results demonstrated that between 2006 and
2018 funded research had become more translational and
clinical in focus (Fig 1A), as shown by statistically signifi-
cant increases (R2 . 0.5) in annual proportional invest-
ment in CSO 4 (Early Detection, Diagnosis, and Prognosis)
and CSO 5 (Treatment). There was a statistically significant
reduction in percent investment in CSO 2 (Etiology). Re-
ductions were also observed for percent investment in CSO
1 (Biology) and CSO 6 (Control, Survivorship, and Out-
comes). Investment levels in CSO 3 (Prevention) varied
between 7% and 9% of the portfolio annually. These trends
across CSO categories were similar in the non-NIH partner
organizations’ investments (Fig 1B), but with a more
marked increase in proportional investment in CSO 4 (Early
Detection, Diagnosis, and Prognosis) over this period than
in the overall portfolio. The data summarized in Figures 1A
and 1B (CSO) provided evidence to support a strategic shift
toward more translational research over the period 2006-
2018, as a higher proportion of research investment was
focused toward the more translational CSO codes.10
However, the overall funding distribution across the
portfolio in 2018 was similar to that in 2006, in terms of
proportional funding awarded to individual CSO codes, and
was consistent with proportional funding patterns identified
in a previous analysis of funding data from the ICRP data-
base undertaken from 2005 to 2008.11 Although investment
levels do not necessarily reflect research priorities, the data
showed (Fig 2) that cancers having the greatest proportional
burden of disease (as assessed by international cancer in-
cidence and mortality statistics) received the highest
proportional level of international research investment.
There were some notable increases in funding for some
cancers such as for pancreatic cancer and brain tumors.
Absolute investment in pancreatic cancer research in-
creased threefold between 2006 ($62M USD) and 2018
($259M USD), as did proportional investment (1.7% in
2006 to 4.6% in 2018), with a significantly increased
focus on research into early diagnosis (CSO 4) and a
corresponding reduction in proportional investment in
etiology (CSO2) (Fig 4). The increased investment in
treatment (CSO 5) was primarily driven by a notable in-
crease in absolute or proportional investment in preclin-
ical discovery and development of systemic therapies
(CSO 5.3) (Fig 4, inset). A previous analysis of ICRP data12
had highlighted the importance of both the government
and the nonprofit sector in promoting research activity for
this cancer, and the present analysis has shown that
significant additional investment has been made. Simi-
larly, absolute investment in research into brain tumors
more than doubled, from $130M USD in 2006 to $391M
USD in 2018, as did proportional investment (3.5% in
2006 to 6.9% in 2018), responding to challenge of
addressing the ongoing and unchanging high levels of
mortality for these cancers and the need for additional
research investment.
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Investment in projects wholly related to childhood cancer
had increased from $144M USD in 2006 to $328M USD in
2018; however, there was no evidence for a significant
increase in annual proportional investment as a percent of
the overall portfolio. Increased investments in 2015-2018
reversed the downward trend from 2012-2014 (not shown)
and the downward trend reported by Loucaides et al13 for
2011-2016. Most of the increase in 2015-2018 was due to
increased funding in the government sector (representing
90% of all investment), but investment in the nonprofit
sector also more than doubled (from $25m USD in 2006 to
$58m USD in 2018). Although funding for CYA is pro-
portional to the incidence of disease overall, it will be im-
portant to ascertain if it is proportional to other measures of
disease burden, such as quality-adjusted life year or
disability-adjusted life year. A detailed analysis of trends in
international childhood cancer research funding will be the
focus of a future publication.
Despite the increasing importance of primary prevention in
addressing the global cancer burden, the overall proportion
of research investment in this area had not changed
markedly between 2006 and 2018. As the small upward
trend in absolute investment was not statistically significant
(R2 , 0.5, not shown) and the trend in annual proportional
investment was not conclusive (Fig 1A), it will be important
to track whether the increased investment in resources and
infrastructure in prevention research (CSO 3.6) leads to
increased primary prevention research in the future.
Survivorship research will also be of increasing importance, as
treatment improvements lead to an increasing number of
cancer survivors. Survivorship (CSO 6.1) encompasses a wide
range of research on living with and beyond cancer, from side
effects to pain control, and supportive care for survivors and
caregivers. This analysis showed that between 2006 and
2018, there was a small uplift in funding (R2 = 0.87) in this
area. A future analysis will focus on text-mining research
abstracts in this area to assess if funded research correlates
with patient and survivor research priorities.
ICRP includes all cancer-related data from the world’s
largest cancer research funder (US National Institutes of
Health), consortia covering the major funders in the United
Kingdom and Canada, and other major funding organi-
zations across the world. Estimates of ICRP’s coverage of
the world governmental and nonprofit investment in cancer
research over 2006-2018 have ranged from 60% to 65%.
Nonpartner funding totals were estimated using two sources:
published annual financial reports of major nonpartner or-
ganizations named in the International Agency for Research
into Cancer’s (IARC) list of world cancer research funders14
and publication volume for partner and nonpartner orga-
nizations using Web of Science as a proxy for research
investment15 (however, analysis suggested that although
high publication volume indicated higher research invest-
ment levels, the correlation was not sufficiently robust to infer
nonpartner funding amounts directly).
Understanding the research funding landscape is key to
making informed funding decisions. Previous analyses of
the research funding landscape have led to strategic de-
cisions by partners to promote research activity in key gap
areas, either in partnership or unilaterally. For example, an
analysis of research into environmental influences in breast
cancer16 raised concern over the general decline in re-
search funding in this area. Using these data and other
evidence, a partner organization (California Breast Cancer
Research Program) launched a call for proposals for ad-
ditional research and capacity building in this area.17
ICRP partner organizations plan to analyze areas with low
investment (or where investment is proportionally low in
comparison with tumor burden) in more depth to under-
stand barriers to research progress. ICRP partners are
working together to analyze three areas in more depth,
namely, barriers to research progress in childhood cancer
(focusing on cancers with a low survival rate), prevention
(understanding barriers to implementation), and survivor-
ship (primarily focusing on whether research activity cor-
relates with patient priorities). As research funders may
wish to conduct their own in-depth analyses of areas of
research funding, to accompany this publication, ICRP has
provided an online cancer research investment data pack
18 to view trends in CSO and cancer site research funding
profiles and geographical investment year-on-year between
2006 and 2018.
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ICRP’s motivation in providing cancer research funding
landscape analyses is to give researchers the tools to
avoid duplication of research, identify potential collab-
orators, and give organizations the capacity to make in-
formed, strategic research funding decisions based on an
understanding of the overall context of international cancer
research funding, especially in the current situation where the
budgets of many organizations are being affected by COVID-
19. Our recent survey of 86 international cancer research
funders indicated that 66% of respondents from charitable or
private foundations expected that their funding available for
cancer research would decrease significantly in 2020 and
2021.19 Although charities or private funders make up only
around 7%-10% of the ICRP portfolio, any reduction in in-
vestment from this sector will be significant globally. This
analysis provides a baseline fromwhich the potential impact of
reduced research budgets because of COVID-19 can be
measured. We anticipate that a full analysis of the impact of
COVID-19 on research investment in 2020 and 2021 will be
possible in 2023.
The ICRP partners welcome additional data from other
funders to help complete the picture of global cancer re-
search funding and to help ensure that cancer research
investments are evidence-based and focused strategically
at an international level.
AFFILIATIONS
1London School of Hygiene and Tropical Medicine, London, United
Kingdom
2Anticancer Fund, Brabant, Belgium
3Institut National du Cancer, Boulogne-Billancourt, France
4International Cancer Research Partnership, Cardiff, United Kingdom
5US National Cancer Institute, Bethesda, MD
6World Cancer Research Fund International, London, United Kingdom
7Melanoma Research Alliance, Washington, DC
8Cancer Australia, Surry Hills, NSW, Australia
9Dutch Cancer Society, Amsterdam, the Netherlands
10National Cancer Research Institute, London, United Kingdom
11National Breast Cancer Foundation, Sydney, NSW, Australia
12Worldwide Cancer Research HQ, Edinburgh, United Kingdom
13Susan G. Komen, Dallas, TX
CORRESPONDING AUTHOR
Lynne Davies, PhD, International Cancer Research Partnership
International House, 10 Churchill Way, Cardiff CF10 2HE, United
Kingdom; e-mail: operations@icrpartnership.org.
PRIOR PRESENTATION
Presented in part (draft headline figures to 2015 and 2016) at the ICRP
annual meetings on April 11, 2018 at the US National Cancer Institute,
Washington DC (https://www.icrpartnership.org/library/file/7429/ICRP_
AnnualMeeting2018_Report.pdf) and on April 3, 2019 at the American
Hotel, Atlanta, GA (https://www.icrpartnership.org/library/file/7740/
ICRP_2019_Annual%20Meeting%20Report.pdf).
SUPPORT
Supported by membership fees and in-kind contributions to the
International Cancer Research Partnership from member organizations.
AUTHOR CONTRIBUTIONS
Conception and design: Rachel Abudu, Lynne Davies, Kalina Duncan, Ian
Lewis, Abdul Mutabbir, Kari Wojtanik
Administrative support: Kalina Duncan
Collection and assembly of data: Lynne Davies, Anna Diaz Font, Linda
Kroeskop-Bossenbroek, Giota Mitrou, Christopher A. Pettigrew, Lynn
Turner, Annemarie Weerman, Kari Wojtanik
Data analysis and interpretation: Gauthier Bouche, Karima Bourougaa,
Lynne Davies, Carla Estaquio, Marc S. Hurlbert, Paul Jackson
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF
INTEREST
The following represents disclosure information provided by authors of
this manuscript. All relationships are considered compensated unless
otherwise noted. Relationships are self-held unless noted. I = Immediate
Family Member, Inst = My Institution. Relationships may not relate to the
subject matter of this manuscript. For more information about ASCO’s
conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.
org/go/authors/author-center.
Open Payments is a public database containing information reported by
companies about payments made to US-licensed physicians (Open
Payments).
Lynne Davies
Consulting or Advisory Role: Innovate UK grant to Proximie Ltd/Cardiff &
Vale University Health Board
Paul Jackson
Stock and Other Ownership Interests: CSL Limited
Marc S. Hurlbert
Uncompensated Relationships: Pfizer
No other potential conflicts of interest were reported.
ACKNOWLEDGMENT
We are grateful to the current ICRP Chair (Dr Naba Bora, Congressionally
Directed Medical Research Programs, US Department of Defense) and
Vice-Chair (Dr Paul Jackson, Cancer Australia) for their support. We are
also grateful to the following individuals for their assistance in the
preparation of data for themanuscript: TJ Koerner, Erin Kruger, and Cheri
Richard (formerly American Cancer Society); Sabrina Joseph (American
Society of Radiation Oncology); Judy Keen (formerly American Society for
Radiation Oncology); Nigel Brockton (American Institute for Cancer
Research); Nicholas J. Anthis, Marion Kavanaugh-Lynch, Katherine
McKenzie, and Senaida Poole (California Breast Cancer Research
Program); Kimberly Badovinac, Louisa Salemi, and Sara Urowitz
(Canadian Cancer Research Alliance); Rachael Barber and Lucy
Devendra (Cancer Research UK); Lisa Towry and Amy Weinstein
(Coalition Against Childhood Cancer); Yuki Sato (Japan Agency for
Medical Research and Development); Michelle Bennett, Laura Brockway
Lunardi, Beth Buschling, Marilyn Gaston, Ed Kyle, Grace Liou, and
Douglas P. Perin (National Cancer Institute, US); Eddie Billingslea
(formerly National Cancer Institute, US); Donna Manross (Pancreatic
Cancer Action Network); Stephanie Reffey (formerly Susan G. Komen);
and Toshio Ogawa (Setsunan University).
Changes in International Cancer Research Funding Patterns
JCO Global Oncology 609
Downloaded from ascopubs.org by 97.90.5.13 on April 28, 2021 from 097.090.005.013
Copyright © 2021 American Society of Clinical Oncology. See https://ascopubs.org/go/authors/open-access for reuse terms.
REFERENCES
1. ICRP: www.icrpartnership.org
2. https://www.icrpartnership.org/db_search
3. Common Scientific Outline (CSO). https://www.icrpartnership.org/cso and ICRP cancer sites https://www.icrpartnership.org/cancer-type-list
4. 2006 Dollars in 2018 | Inflation Calculator. U.S. Official Inflation Data, Alioth Finance. http://www.in2013dollars.com/
5. International Classification of Diseases (ICD-10). https://icd.who.int/browse10/2019/en
6. Bray F, Ferlay J, Soerjomataram I, et al: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185
countries. CA Cancer J Clin 68:394-424, 2018
7. Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 33:159-174, 1977
8. Cohen J: Weighed kappa: Nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull 70:213-220, 1968
9. http://dfreelon.org/utils/recalfront/recal2/
10. International Cancer Research Partnership Translational Cancer Methodology Report, 2015 https://www.icrpartnership.org/library/file/7/ICRP_Translational_
Methodology_2015.pdf
11. Cancer Research Funding from an International Perspective: Report from the International Cancer Research Partnership. https://www.icrpartnership.org/
library/file/4/ICRP_Report_2005-08.pdf, 2012
12. Hendifar A, Davies L, Tulli R: Private funding for pancreatic cancer research: More than a chip shot. Gastroenterology 152:918-921, 2017
13. Loucaides EM, Fitchett EJA, Sullivan R, et al: Global public and philanthropic investment in childhood cancer research: Systematic analysis of research funding,
2008-16. Lancet Oncol 20:e672-e684, 2019
14. Schmutz A, Salignat C, Plotkina D, et al: Mapping the global cancer research funding landscape. JNCI Cancer Spectr 3:pkz069, 2019
15. Web of Science. https://clarivate.com/products/web-of-science/
16. Environmental Influences on Breast Cancer: An Analysis of the International Cancer Research Portfolio, 2012. https://www.icrpartnership.org/library/file/5/
ICRP_EnvInfluences_BreastCancer_2014.pdf
17. Sutton P, Kavanaugh-Lynch MHE, Plumb M, et al: California breast cancer prevention initiatives: Setting a research agenda for prevention. Reprod Toxicol
54:11-18, 2015
18. https://www.icrpartnership.org/library/file/7963/ICRP_2006-2018_JGOTrendReport.pdf
19. Impact of COVID-19 on Cancer Research Funders: An International Survey. https://www.icrpartnership.org/library/file/7904/ICRP_Covid-19_CancerFunders_
ImpactSurvey_2020.pdf, 2020
n n n
Abudu et al
610 © 2021 by American Society of Clinical Oncology
Downloaded from ascopubs.org by 97.90.5.13 on April 28, 2021 from 097.090.005.013
Copyright © 2021 American Society of Clinical Oncology. See https://ascopubs.org/go/authors/open-access for reuse terms.
